Vabametkib

DB21629InvestigationalSmall molecule

Vabametkib is a small molecule drug. Vabametkib is under investigation in clinical trial NCT05541822 (To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid... Vabametkib has a monoisotopic molecular weight of 566.3 Da.

Mechanism: Pharmacologically active on Hepatocyte growth factor receptor
Curator reviewed
Formula / weight: C₂₉H₃₄N₁₂O · 566.674 g/mol (avg)

Resolves to

Compound

UNIIXT5T3BT4QPCAS1571903-56-4ChEMBLCHEMBL3950590

Structure

InChIKeyPQJGYYZYYMVBDF-VWLOTQADSA-NSMILESCN1C=C(C=N1)C1=CN=C2N=NN(C[C@@H]3CN(CCO3)C3=NC=C(C=N3)C3=CC=C(CN4CCN(C)CC4)C=C3)C2=N1

Targets

P08581MET

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vabametkib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account